CA2908029C - Radiolabelling process - Google Patents

Radiolabelling process Download PDF

Info

Publication number
CA2908029C
CA2908029C CA2908029A CA2908029A CA2908029C CA 2908029 C CA2908029 C CA 2908029C CA 2908029 A CA2908029 A CA 2908029A CA 2908029 A CA2908029 A CA 2908029A CA 2908029 C CA2908029 C CA 2908029C
Authority
CA
Canada
Prior art keywords
formula
acid
compound
substituent
facbc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2908029A
Other languages
English (en)
French (fr)
Other versions
CA2908029A1 (en
Inventor
Torild Wickstrom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of CA2908029A1 publication Critical patent/CA2908029A1/en
Application granted granted Critical
Publication of CA2908029C publication Critical patent/CA2908029C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0402Organic compounds carboxylic acid carriers, fatty acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0404Lipids, e.g. triglycerides; Polycationic carriers
    • A61K51/0406Amines, polyamines, e.g. spermine, spermidine, amino acids, (bis)guanidines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001Acyclic or carbocyclic compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • C07C227/20Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters by hydrolysis of N-acylated amino-acids or derivatives thereof, e.g. hydrolysis of carbamates
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/377Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/15Saturated compounds containing halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05Isotopically modified compounds, e.g. labelled
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA2908029A 2013-03-28 2014-03-28 Radiolabelling process Active CA2908029C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1305687.4A GB201305687D0 (en) 2013-03-28 2013-03-28 Radiolabelling process
GB1305687.4 2013-03-28
PCT/EP2014/056344 WO2014154886A1 (en) 2013-03-28 2014-03-28 Radiolabelling process

Publications (2)

Publication Number Publication Date
CA2908029A1 CA2908029A1 (en) 2014-10-02
CA2908029C true CA2908029C (en) 2021-05-04

Family

ID=48444922

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2908029A Active CA2908029C (en) 2013-03-28 2014-03-28 Radiolabelling process

Country Status (12)

Country Link
US (2) US9999692B2 (enExample)
EP (1) EP2978456B1 (enExample)
JP (1) JP6500011B2 (enExample)
KR (1) KR102218249B1 (enExample)
CN (1) CN105120905B (enExample)
AU (1) AU2014242897B2 (enExample)
CA (1) CA2908029C (enExample)
ES (1) ES2864702T3 (enExample)
GB (1) GB201305687D0 (enExample)
MX (1) MX368061B (enExample)
RU (1) RU2675371C2 (enExample)
WO (1) WO2014154886A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305687D0 (en) 2013-03-28 2013-05-15 Ge Healthcare Ltd Radiolabelling process
US20220001034A1 (en) * 2014-06-30 2022-01-06 Ge Healthcare Limited Novel formulation and method of synthesis
GB201621864D0 (en) * 2016-12-21 2017-02-01 Ge Healthcare Ltd Solid phase conditioning

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5808146A (en) 1995-11-09 1998-09-15 Emory University Amino acid analogs for tumor imaging
JP4989467B2 (ja) * 2005-05-23 2012-08-01 日本メジフィジックス株式会社 新規有機化合物及び該化合物を利用した放射性ハロゲン標識有機化合物の製造方法
EP1893244A4 (en) 2005-06-23 2009-06-24 Univ Emory AGENTS FOR IMAGING
CA2612187C (en) 2005-06-23 2013-05-07 Emory University Stereoselective synthesis of amino acid analogs for tumor imaging
ES2380372T3 (es) * 2006-05-11 2012-05-11 Nihon Medi-Physics Co., Ltd. Procedimiento para la producción de compuesto orgánico marcado con flúor radioactivo
KR101497406B1 (ko) 2006-12-21 2015-03-02 니혼 메디피직스 가부시키가이샤 방사성 화상 진단제
JP5258583B2 (ja) 2007-02-13 2013-08-07 日本メジフィジックス株式会社 放射性画像診断剤の製造方法
JP5732198B2 (ja) 2007-12-19 2015-06-10 日本メジフィジックス株式会社 放射性フッ素標識有機化合物の製造方法
EP2509637B1 (en) 2009-10-08 2016-08-10 GE Healthcare Limited Purification method
EP2793954B1 (en) * 2011-12-21 2020-10-21 GE Healthcare Limited 18f-fluciclovine compositions in citrate buffers
AU2011351550B2 (en) 2010-12-29 2017-02-02 Ge Healthcare Limited Eluent solution
GB201305687D0 (en) 2013-03-28 2013-05-15 Ge Healthcare Ltd Radiolabelling process

Also Published As

Publication number Publication date
EP2978456A1 (en) 2016-02-03
KR20150136598A (ko) 2015-12-07
ES2864702T3 (es) 2021-10-14
CA2908029A1 (en) 2014-10-02
CN105120905B (zh) 2021-07-06
KR102218249B1 (ko) 2021-02-22
US20180177900A1 (en) 2018-06-28
AU2014242897A1 (en) 2015-08-27
JP2016515564A (ja) 2016-05-30
MX368061B (es) 2019-09-18
US20160051710A1 (en) 2016-02-25
BR112015024344A2 (pt) 2017-07-18
RU2015138540A3 (enExample) 2018-03-01
GB201305687D0 (en) 2013-05-15
EP2978456B1 (en) 2021-03-17
AU2014242897B2 (en) 2018-11-08
CN105120905A (zh) 2015-12-02
JP6500011B2 (ja) 2019-04-10
WO2014154886A1 (en) 2014-10-02
RU2675371C2 (ru) 2018-12-19
RU2015138540A (ru) 2017-05-03
US9999692B2 (en) 2018-06-19
MX2015013801A (es) 2016-02-16

Similar Documents

Publication Publication Date Title
EP3766522B1 (en) Automated method for the preparation of 18f-fluciclovine compositions
US10023525B2 (en) Preparation of 18F-fluciclovine
CA2953641C (en) Novel formulation and method of synthesis
CA2908029C (en) Radiolabelling process
EP2793954B1 (en) 18f-fluciclovine compositions in citrate buffers
GB2561122B (en) Composition comprising [18F]-Fluciclovine
BR112015024344B1 (pt) Método para obter uma composição
NZ624250A (en) 18f-fluciclovine compositions in citrate buffers
NZ624250B2 (en) 18f-fluciclovine compositions in citrate buffers
HK1197368A (en) 18f - fluciclovine compositions in citrate buffers

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190314

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250227

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250227